📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Medite Cancer Diagnostics

1.1 - Company Overview

Medite Cancer Diagnostics Logo

Medite Cancer Diagnostics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of development, manufacture, and distribution as a mid-sized industrial corporation.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Medite Cancer Diagnostics

Verastem Logo

Verastem

HQ: United States Website
  • Description: Provider of biopharmaceutical therapies targeting RAS/MAPK pathway–driven cancers, developing avutometinib, a RAF/MEK clamp designed to block RAF and MEK signaling in the RAS pathway, and defactinib, a FAK inhibitor used with avutometinib to block compensatory FAK activation and enhance tumor growth blockade.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Verastem company profile →
Aurealis Therapeutics Logo

Aurealis Therapeutics

HQ: Finland Website
  • Description: Provider of cell and gene therapies for chronic wounds and complex inflammatory diseases. Its four-in-one biologic AUP-16 is a genetically engineered Lactococcus cremoris producing therapeutic proteins to halt inflammation, induce blood vessel growth, and promote tissue formation for diabetic foot, venous leg, and pressure ulcers. AUP-55 is in pre-clinical development for ovarian and bladder cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Aurealis Therapeutics company profile →
Point Biopharma Logo

Point Biopharma

HQ: United States Website
  • Description: Provider of radioligand therapies for cancer, with a globally focused platform for the clinical development and commercialization of radioligands. Combines a portfolio of radiopharmaceutical assets with a seasoned management team and expertise in radioisotopes.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Point Biopharma company profile →
Admune Therapeutics Logo

Admune Therapeutics

HQ: United States Website
  • Description: Provider of development and delivery of cytokine therapy drugs for cancer as a clinical-stage biotech company.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Admune Therapeutics company profile →
Incyte Logo

Incyte

HQ: United States Website
  • Description: Provider of drug discovery and development focused on building a proprietary pipeline of novel small molecule drugs.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Incyte company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Medite Cancer Diagnostics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Medite Cancer Diagnostics

2.2 - Growth funds investing in similar companies to Medite Cancer Diagnostics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Medite Cancer Diagnostics

4.2 - Public trading comparable groups for Medite Cancer Diagnostics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Medite Cancer Diagnostics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Medite Cancer Diagnostics

What does Medite Cancer Diagnostics do?

Medite Cancer Diagnostics is a provider of development, manufacture, and distribution as a mid-sized industrial corporation.

Who are Medite Cancer Diagnostics's competitors?

Medite Cancer Diagnostics's competitors and similar companies include Verastem, Aurealis Therapeutics, Point Biopharma, Admune Therapeutics, and Incyte.

Where is Medite Cancer Diagnostics headquartered?

Medite Cancer Diagnostics is headquartered in United States.

How many employees does Medite Cancer Diagnostics have?

Medite Cancer Diagnostics has 1,000 employees 🔒.

When was Medite Cancer Diagnostics founded?

Medite Cancer Diagnostics was founded in 2010 🔒.

What sector and industry vertical is Medite Cancer Diagnostics in?

Medite Cancer Diagnostics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Medite Cancer Diagnostics

Who are the top strategic acquirers in Medite Cancer Diagnostics's sector and industry

Top strategic M&A buyers and acquirers in Medite Cancer Diagnostics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Medite Cancer Diagnostics?

Top strategic M&A buyers groups and sectors for Medite Cancer Diagnostics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Medite Cancer Diagnostics's sector and industry vertical

Which are the top PE firms investing in Medite Cancer Diagnostics's sector and industry vertical?

Top PE firms investing in Medite Cancer Diagnostics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Medite Cancer Diagnostics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Medite Cancer Diagnostics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Medite Cancer Diagnostics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Medite Cancer Diagnostics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Medite Cancer Diagnostics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Medite Cancer Diagnostics?

The key public trading comparables and valuation benchmarks for Medite Cancer Diagnostics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Medite Cancer Diagnostics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Medite Cancer Diagnostics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Medite Cancer Diagnostics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Medite Cancer Diagnostics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Medite Cancer Diagnostics's' sector and industry vertical?

Access recent funding rounds and capital raises in Medite Cancer Diagnostics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Medite Cancer Diagnostics